1,721,415 research outputs found
Survival of patients with PH+ Chronic myeloid leukemia relapsing after an allogeneic stem cell transplant.
No full textAllogeneic blood or marrow stem cell transplantation
(SCT) from an HLA-identical sibling is the treatment
of choice for younger patients with chronic
myeloid leukemia (CML). Using standard conditioning
regimens and graft-versus-host disease (GvHD)
prophylaxis, more than 50% of patients are alive and
well with no sign of disease more than 10 years from
transplant. Transplant-related mortality and relapse
remain the major obstacles to success. Relapse
occurs in about 20% of patients transplanted in first
chronic phase (CP) with unmanipulated marrow
cells; the risk increases to more than 50% for patients
transplanted at a later stage of the disease or those
transplanted in first CP with a T-cell depleted marrow.
Not all patients who relapse will die as a consequence
of disease recurrence. Immune modulation
to achieve a graft-versus-leukemia effect, standard
therapy for CML, or second allogeneic SCT have all
been used with variable degrees of success. Thus
some patients may regain complete remission of the
disease following withdrawal of immunosuppression,
donor lymphocyte infusions (DLI), treatment with α-
interferon (IFN), or a second allogeneic SCT. Features
of both the patient and the disease influence the
efficacy of these salvage treatment
Quality assessment of cord blood units selected for unrelated transplantation: a transplant center perspective
No full textCord blood units (CBUs) are increasingly being used for unrelated allogeneic stem cell transplantation and their selection is mainly done according to pre-freezing cell dose and HLA donor/recipient compatibility. The main practical advantage of cord blood transplant (CBT) is represented by an easy and quick CBU procurement, due to the possibility of long-term storage of fully HLA typed CBUs assessed for cell dose and infectious contamination. The main disadvantage consists in a limited cell dose, with the consequent risk of graft failure or engraftment delay. In order to warrant the safety and the efficiency of CBUs selected for clinical use, transplant physicians may check CBU characteristics by requiring quality assessments (QAs) to the cord blood bank (CBB), to be performed on segments attached to and cryopreserved with the bags. However, there is a wide variability concerning CBU-QA with regard to the pre-transplant "release tests", mainly due to limited availability of segments attached to the CBU and of maternal samples and to difficult communication between Transplant Centres (TCs) and CBBs. The aim of this article is to describe a TC perspective during CBU selection for unrelated transplant, in order to identify an appropriate QA scheme and define the timing when the results need to be acquired. By analyzing the available data, this article describes a model of TC-QA policy able to guide the clinician from CBU selection through the infusion, with the ultimate aim of improving the transplant clinical outcome
Are we sure we all do the same things? Results from a GITMO survey on basic practices in allogeneic bone marrow transplantation
No full textDoes the volume reduction manipulation before cryopreservation influence cord blood cell recovery pretransplant?
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
